摘要
目的:观察贝伐珠单抗联合伊立替康和卡培他滨方案治疗转移性结直肠癌的临床疗效和安全性。方法:回顾性分析天津医科大学肿瘤医院2008年1月至2011年12月收治的经病理学确诊的晚期结直肠癌53例,其中试验组27例,应用贝伐珠单抗联合伊立替康及卡培他滨治疗,对照组单纯应用伊立替康及卡培他滨治疗方案。比较两组临床疗效和安全性。结果:近期疗效比较,试验组与对照组的CR+PR(缓解率)差异无统计学意义(RR=24.15%,21.91%,P>0.05),疾病控制率(CR+PR+SD)差异有统计学意义(86.30%,61.24%,P<0.05)。远期疗效比较,两组TTP分别为10.3个月、6.7个月,中位生存时间为18.2个月、13.6个月,差异有统计学意义(P<0.05)。两组不良反应没有差异,但试验组高血压发生率为27%,表现为舒张压升高,对症治疗后缓解。结论:贝伐珠单抗联合伊立替康及卡培他滨方案较单纯化疗可延长患者生存且疾病控制率好,不良反应无明显增加,可成为一线治疗方案。
Objective:Observation of efifcacy and safety of bevacizumab plus capecitabine and irinotecan in the treatment of metastatic colorectal cancer.Methods:Retrospective analysis of 53 patients who were confirmed by pathology with metastatic colorectal cancer from January 2008 to December 2011.27 patients received bevacizumab(7.5 mg·kg^(-1))plus capecitabine and irinotecan until disease progression or intolerable toxicity occurred.The other patients simply applied to the above chemotherapy.Results:In the recent therapeutic efifcacy,there was no statisticaly signiifcant response rate difference(CR+PR=24.15%,21.91%,P>0.05)between experimental group and control group,disease control rates(CR+PR+SD)difference was statisticaly signiifcant(86.30%,61.24%,P<0.05).In the long-term efifcacy comparison of two groups,TTP is 10.3 months vs.6.7 months,respectively,the median survival time was 18.2 months vs.13.6 months,the difference was statisticaly significant(P<0.05).Adverse events(AEs)were no difference between two groups,but the incidence of hypertension was 27%in experimental group who showed the diastolic pressure and they were aleviated after medication.Conclusion:bevacizumab plus capecitabine and irinotecan is an effective and safe regimen as a ifrst-line treatment for patients with mCRC in China.
作者
王粹
胡冬至
胡均
王华庆
WANG Cui;HU Dong-zhi;HU Jun;WANG Hua-qing(Department of Colorectal Cancer,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center of Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin 300060,China;Department of Lymphoma,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center of Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin 300060,China)
出处
《临床药物治疗杂志》
2014年第S01期24-27,共4页
Clinical Medication Journal
基金
国家自然科学基金资助项目(81101870)
关键词
结直肠癌
贝伐珠单抗
化疗
colorectal cancer
bevacizumab
chemotherapy
作者简介
通讯作者:王华庆,E-mail:huaqingw@163.com
